When do the ELREXFIO patents expire, and when will biosimilar ELREXFIO enter the market?

Sponsor	Phase
Pfizer	Phase 4

Last updated: November 2, 2026

ELREXFIO, Pfizer’s elranatamab-bcmm, is a BCMA-directed CD3-directed bispecific antibody for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy. Its commercial opportunity is driven by rapid uptake of off-the-shelf bispecific therapy, increasing treatment exposure in earlier lines, and the need for alternatives to CAR-T therapy. Its principal constraints are a heavily pretreated label, infection and cytokine-release-syndrome management, competition from Johnson & Johnson and Legend Biotech’s TECVAYLI, and eventual competition from other BCMA bispecifics and CAR-T products.

What is ELREXFIO and which market does it target?

ELREXFIO is a subcutaneous, fixed-dose bispecific antibody that binds B-cell maturation antigen, or BCMA, on myeloma cells and CD3 on T cells. The FDA granted accelerated approval on August 14, 2023, for adults with relapsed or refractory multiple myeloma after at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval was based on results from the MagnetisMM-3 study. [1]

The drug is used with step-up dosing to reduce the risk of cytokine release syndrome, followed by weekly or less frequent maintenance dosing depending on the treatment regimen and label status. Administration requires a controlled setting during initiation and monitoring for infections, cytopenias, hypogammaglobulinemia, and neurologic toxicity.

ELREXFIO product profile

Attribute	ELREXFIO
Active ingredient	Elranatamab-bcmm
Manufacturer	Pfizer
Modality	BCMA x CD3 bispecific antibody
Route	Subcutaneous injection
Initial FDA approval	August 14, 2023
FDA pathway	Accelerated approval
Initial population	Adults with relapsed or refractory multiple myeloma after at least four prior lines
Key study	MagnetisMM-3
Main competitors	TECVAYLI, CARVYKTI, ABECMA, clinical-stage BCMA and GPRC5D bispecifics
Principal risks	Cytokine release syndrome, infections, cytopenias, hypogammaglobulinemia, neurotoxicity

How large is the ELREXFIO commercial opportunity?

The addressable population is smaller than the total multiple myeloma market because the initial label requires four or more prior therapies. The commercial value is still meaningful because these patients have few effective options and are often treated in specialist centers with high drug utilization.

The main growth opportunity is label expansion into earlier treatment lines. Earlier-line use would materially increase the number of eligible patients and extend treatment duration. It would also place ELREXFIO in direct competition with CAR-T therapies and other bispecific antibodies rather than limiting it to salvage treatment.

The market has several structural advantages:

Multiple myeloma is a chronic disease with repeated treatment lines.
BCMA expression is common in advanced myeloma.
Subcutaneous administration can be operationally simpler than an autologous CAR-T procedure.
Bispecific therapy does not require leukapheresis, manufacturing slots, or a prolonged vein-to-vein interval.
Relapsed patients often require treatment quickly.

The principal commercial limitation is that the product remains a high-acuity therapy. Hospitals must manage step-up dosing, infection surveillance, immunoglobulin replacement, and adverse-event protocols. That limits immediate use in lower-capability community practices.

What is the financial trajectory for ELREXFIO?

Pfizer has identified ELREXFIO as a growth product within its oncology portfolio, but it does not separately disclose product-level operating profit, gross margin, or commercial spending. Product revenue is the most useful public measure of trajectory. Pfizer reported limited launch-year sales in 2023, followed by materially higher sales in 2024 as treatment-center activation, awareness, and patient access expanded. [2]

Revenue trajectory

Period	Commercial status	Financial interpretation
2023	U.S. launch in August	Initial revenue reflected limited launch duration and center activation
2024	Broadening U.S. uptake and international commercialization	Revenue growth reflected increasing patient starts and repeat maintenance dosing
2025 onward	Expansion depends on label development and competitive positioning	Earlier-line indications would be the largest value driver

The revenue model differs from a one-time cell therapy. ELREXFIO can generate recurring revenue while patients remain on treatment. That creates a cumulative revenue opportunity from patient persistence, although discontinuations caused by progression, adverse events, infection, or alternative treatment reduce duration.

What will determine whether ELREXFIO becomes a blockbuster?

Four variables will determine the product’s path toward blockbuster sales:

Label expansion. A move into earlier lines would increase the treated population by several multiples relative to the current fourth-line-plus market.
Treatment duration. Continued dosing creates recurring revenue, but the median duration is limited by disease progression and tolerability.
Site-of-care adoption. Subcutaneous delivery supports outpatient use, but monitoring requirements may slow community adoption.
Relative clinical performance. Physicians will compare response depth, duration of response, infection burden, dosing convenience, and operational complexity with TECVAYLI and CAR-T products.

A downside case would involve durable use only in late-line patients, continued competition from TECVAYLI, and substitution by CAR-T in medically fit patients. An upside case would involve earlier-line positioning, lower-intensity outpatient administration, and a differentiated safety or dosing profile.

How does ELREXFIO compare with TECVAYLI and CAR-T therapies?

ELREXFIO competes most directly with TECVAYLI, another off-the-shelf BCMA-directed bispecific antibody. TECVAYLI is marketed by Johnson & Johnson and Genmab. Both drugs are designed for heavily pretreated multiple myeloma and carry class risks related to cytokine release syndrome and infections.

Factor	ELREXFIO	TECVAYLI	BCMA CAR-T therapies
Modality	Bispecific antibody	Bispecific antibody	Autologous cell therapy
Availability	Off-the-shelf	Off-the-shelf	Limited by manufacturing capacity
Administration	Subcutaneous	Subcutaneous	One-time infusion after manufacturing
Manufacturing delay	None after product supply	None after product supply	Significant vein-to-vein interval
Revenue model	Recurring treatment	Recurring treatment	Primarily one-time treatment revenue
Operational burden	Step-up dosing and monitoring	Step-up dosing and monitoring	Leukapheresis, lymphodepletion, infusion, monitoring
Key commercial advantage	Pfizer oncology infrastructure and subcutaneous delivery	First-mover position and broad commercial infrastructure	Deep responses and finite treatment course
Key risk	Late-line label and competitive crowding	Same-class competition and infection risk	Manufacturing delay, cost, and treatment-center capacity

CARVYKTI, marketed by Johnson & Johnson and Legend Biotech, and ABECMA, marketed by Bristol Myers Squibb and 2seventy bio, compete for patients who are eligible for cellular therapy. The choice depends on disease urgency, performance status, referral access, manufacturing capacity, prior BCMA exposure, and physician preference.

What FDA regulatory milestones affect ELREXFIO sales?

The initial FDA approval was accelerated, meaning continued approval depends on confirmatory evidence verifying clinical benefit. Pfizer’s MagnetisMM development program is designed to support broader use and additional treatment settings. [1, 3]

The most commercially important regulatory developments are:

Conversion of accelerated approval to regular approval.
Expansion into earlier treatment lines.
Use after or before CAR-T therapy.
Less frequent maintenance dosing.
International approvals and reimbursement decisions.
Data supporting use in patients with prior BCMA-directed therapy.

Earlier-line approval would be more valuable than a narrow expansion among heavily pretreated patients because it would increase both patient volume and treatment duration.

What patents protect ELREXFIO, and when does it lose exclusivity?

ELREXFIO is a biologic, so its U.S. exclusivity framework differs from that of a small-molecule drug.

Orange Book status

ELREXFIO does not have an Orange Book listing because the Orange Book covers approved drug products, primarily small molecules, rather than biologic reference products. Biologic exclusivity and biosimilar competition are addressed through the Public Health Service Act and the FDA’s Purple Book framework. [4]

Biosimilar exclusivity

The reference product receives 12 years of U.S. reference-product exclusivity from the date of first licensure under the Biologics Price Competition and Innovation Act. Based on the August 2023 U.S. approval, the statutory reference-product exclusivity period would generally run to approximately August 2035, subject to the precise first-licensure determination and any pediatric extension. [5]

A biosimilar applicant may begin certain development and regulatory activities before that date, but FDA approval cannot take effect during the statutory exclusivity period. Patent rights could extend beyond or interact with that period.

Paragraph IV challenges

Paragraph IV litigation is a Hatch-Waxman mechanism for small-molecule drugs. It does not apply to ELREXFIO in the same way because ELREXFIO is a biologic. A biosimilar applicant instead follows the BPCIA patent-exchange and litigation framework, commonly called the patent dance.

Patent strength

The commercial patent estate is likely to include claims covering the antibody, binding characteristics, sequence variants, use in multiple myeloma, dosing schedules, formulations, and manufacturing processes. The practical strength of that estate depends on claim scope, written-description support, prosecution history, validity, and whether follow-on patents cover commercially necessary dosing or formulation features.

The Purple Book does not provide an Orange Book-style, definitive public list of all patents that may be asserted against a biosimilar. Pfizer’s patent strategy therefore cannot be assessed solely from a product database listing.

What formulation and method-of-use rights matter?

The most commercially relevant follow-on rights are likely to involve:

Subcutaneous dosing.
Step-up dosing schedules.
Weekly and less frequent maintenance regimens.
Treatment after specific prior therapies.
Combination treatment with other myeloma agents.
Management of cytokine release syndrome and infection risk.
Formulation stability and manufacturing controls.

Method-of-use patents can be commercially relevant even when composition-of-matter protection is challenged. Their value is highest when the patented method corresponds to the FDA-approved dosing regimen and physicians are likely to use that regimen routinely.

Manufacturing patents may also delay biosimilar substitution if they cover cell-line development, antibody production, purification, or formulation. They are less certain barriers than valid composition or use claims because biosimilar applicants can sometimes design around process claims.

Which companies are challenging or competing with ELREXFIO?

The principal competitive companies are:

Johnson & Johnson and Genmab, with TECVAYLI and CARVYKTI-related commercial infrastructure.
Bristol Myers Squibb and 2seventy bio, with ABECMA.
Regeneron, with investigational bispecific and myeloma programs.
Roche, with investigational T-cell engager programs.
AbbVie, Genmab, and other developers pursuing bispecific and antibody-based multiple myeloma therapies.
Emerging developers targeting GPRC5D, FcRH5, and other myeloma antigens.

No conventional generic launch is expected because ELREXFIO is a biologic. The relevant future threat is biosimilar competition, together with branded substitution by next-generation bispecifics and cellular therapies.

What litigation and settlement risks affect ELREXFIO?

A public, product-specific Paragraph IV litigation pathway does not apply. The principal legal risks are potential BPCIA litigation, patent challenges by biosimilar developers, inventorship or ownership disputes, and disputes over antibody sequence, dosing, formulation, and manufacturing claims.

No major publicly established ELREXFIO settlement agreement should be treated as a confirmed market event without a filed court record or company disclosure. Settlement terms in biologic patent disputes can determine the first commercial biosimilar date, but those terms are often confidential.

What generic or biosimilar launch scenarios exist?

Three launch scenarios are commercially relevant:

Early biosimilar entry near statutory exclusivity expiry

A biosimilar could seek approval before the end of patent protection but launch only after resolving applicable patent disputes or reaching a settlement. This would produce the largest pricing pressure.

Delayed entry from patent litigation

Valid patents covering the antibody, dosing regimen, or commercially necessary formulation could delay launch beyond the end of reference-product exclusivity.

Branded substitution before biosimilar entry

A newer bispecific or CAR-T product could reduce ELREXFIO revenue before biosimilar competition begins. This is especially likely if a competitor demonstrates earlier-line efficacy, less frequent dosing, or a lower infection burden.

How strong is the ELREXFIO commercial position?

ELREXFIO has a credible long-term position because it combines off-the-shelf availability with subcutaneous delivery and a large multiple myeloma treatment ecosystem. Pfizer’s oncology sales force and global infrastructure support access and reimbursement.

The estate and commercial position are weaker than those of a first-in-class product with broad earlier-line use if ELREXFIO remains confined to late-line treatment. Competition is already established, and the class has meaningful safety-management requirements. The central investment question is whether Pfizer can move the product from a late-line rescue therapy into a durable component of earlier myeloma treatment.

Key Takeaways

ELREXFIO is Pfizer’s BCMA-directed, subcutaneous bispecific antibody for relapsed or refractory multiple myeloma.
Its 2023 launch was followed by substantially higher commercial activity in 2024.
The largest revenue catalyst is expansion into earlier treatment lines.
TECVAYLI is the closest bispecific competitor; CARVYKTI and ABECMA compete for eligible patients.
ELREXFIO is not an Orange Book product. Biosimilar competition is governed by the BPCIA and Purple Book framework.
U.S. reference-product exclusivity generally runs for 12 years from first licensure, implying a statutory horizon around 2035 based on the 2023 approval.
The main long-term risks are class crowding, infection management, late-line positioning, and substitution by CAR-T or next-generation bispecific therapies.
Pfizer’s product-level profitability is not publicly disclosed, so revenue growth and label expansion are the key observable commercial indicators.

FAQs

Is ELREXFIO a CAR-T therapy?

No. ELREXFIO is an off-the-shelf bispecific antibody that redirects T cells to BCMA-positive myeloma cells. CAR-T therapies require collection and genetic modification of the patient’s T cells.

Does ELREXFIO have an Orange Book patent listing?

No. ELREXFIO is a biologic, so the Orange Book is not the principal U.S. patent database. Biosimilar and reference-product information is handled through the Purple Book and BPCIA framework.

Can a generic company file a Paragraph IV challenge against ELREXFIO?

No. Paragraph IV applies to Hatch-Waxman small-molecule drug applications. A company seeking to challenge ELREXFIO would generally pursue the BPCIA biosimilar pathway.

What is the largest risk to ELREXFIO revenue?

The largest risk is failure to expand beyond the heavily pretreated population while competing bispecific antibodies and CAR-T therapies gain use in earlier treatment lines.

When could an ELREXFIO biosimilar reach the U.S. market?

The statutory reference-product exclusivity period generally points to a date around August 2035 based on ELREXFIO’s August 2023 first licensure. Patent litigation, settlements, pediatric exclusivity, and other legal factors could change the effective launch date.

References

U.S. Food and Drug Administration. (2023). FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma.
Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024.
Pfizer Inc. (2024). ELREXFIO clinical development and MagnetisMM program materials.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Health Service Act §351(k), 42 U.S.C. §262.

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ELREXFIO

ELREXFIO Drug Profile

Summary for Tradename: ELREXFIO

Recent Clinical Trials for ELREXFIO

Note on Biologic Patents

1) High Certainty: US Patents for ELREXFIO Derived from Brand-Side Litigation

2) High Certainty: US Patents for ELREXFIO Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for ELREXFIO Derived from Patent Text Search

ELREXFIO Market Dynamics, Revenue Trajectory, Competition, and Patent Outlook